Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566

Error in Table

In the original publication [1], there was a mistake in Table 1 as published. In certain instances, UGT1A1 allele frequencies were inadvertently used to describe phenotype frequencies. The corrected

Table 1. Example UGT1A1 alleles, predicted phenotype function, and frequencies among racial/ethic groups.

Example UGT1A1 Alleles and Predicted Function
Star Nomenclature		Variant Type		Allele Function α
UGT1A1*36		(TA)5		Increased Function
UGT1A1*1		(TA)6		Normal Function
UGT1A1*6		(211G > A)		Decreased Function
UGT1A1*28		(TA)7		Decreased Function
UGT1A1*37		(TA)8		Decreased Function
Predicted UGT1A1 Phenotypes Based on Commonly Observed Diplotypes
Predicted UGT1A1 Phenotype		Frequently Reported Diplotypes [Less Commonly Investigated Diplotypes] β
Normal Metabolizer (NM)		*1/*1 [*1/*36, *36/*36]
Intermediate Metabolizer (IM)		*1/*28, *1/*6 [*1/*37, *6/*36, *28/*36, *36/*37]
Poor Metabolizer (PM)		*6/*6, *6/*28, *28/*28 [*6/*37, *28/*37, *37/*37]
UGT1A1 Allele Frequencies Among Race/Ethnic Groups µ
UGT1A1 Allele	African American/ Afro-Caribbean	Central/ South Asian	East Asian	European	Latino	Sub-Saharan African
*1	3%	54%	71%	36%	21%	49%
*6	<1%	4%	15%	<1%	1%	0%
*28	37%	41%	15%	32%	40%	40%
*36	8%	0%	0%	0%	0%	7%
*37	6%	0%	0%	<1%	0%	4%

α: UGT1A1 allele function per CPIC and prior investigations [6,11]. β: While allelic diversity continues to be recognized, reference laboratories may only test for certain polymorphisms such as *1, *6, and *28. µ: Table recreated from CPIC UGT1A1 Frequency Table [6,12].

appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.